Sirnaomics Investor
Sirnaomics is a clinical-stage biopharmaceutical company developing therapeutics for critical human diseases by using RNA interference (RNAi) technology.
The RNAi technology is used to discover and develop novel therapeutics with a focus on oncology, anti-fibrotic therapeutics, and viral infection. Its proprietary Polypeptide Nano-Particle (PNP) technology is used for small interfering RNA (siRNA) drug delivery. This technology allows accessing the tumor micro-environment (TME), as well as various cell types in the liver.
Sirnaomics was founded by Patrick Y. Lu and David M. Evans in 2007 and is based in Gaithersburg, Maryland.
Investor Type:
Healthcare Company
Employee Number:
51-100
Headquarters:
Germantown,Maryland,United States,North America
Founded Date:
2007-01-01
City:
Germantown
Region:
Maryland
Country:
United States
Funding Rounds:
4
Founders:
David Evans,George Ji,Patrick Lu
Ipo Status:
public